Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma.

Autor: Eckmann J; Roche Innovation Center Munich, Germany., Fauti T; Roche Innovation Center Zurich, Switzerland., Biehl M; Roche Innovation Center Zurich, Switzerland., Zabaleta A; Cancer Center Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicadas (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), Pamplona, Spain., Blanco L; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), Pamplona, Spain., Lelios I; Roche Innovation Center Basel, Switzerland., Gottwald S; Roche Innovation Center Munich, Germany., Rae R; Roche Innovation Center Munich, Germany., Lechner S; Roche Innovation Center Munich, Germany., Bayer C; Roche Innovation Center Munich, Germany., Dekempe Q; Roche Innovation Center Munich, Germany., Osl F; Roche Innovation Center Munich, Germany., Carrié N; centre de recherche en cancérologie de toulouse INSERM U1037, toulouse, France., Kassem S; Centre de rechecrche en cancérologie de Toulouse de Inserm U1037, Toulouse, France., Lorenz S; Roche Innovation Center Munich, Germany., Christopeit T; Roche Innovation Center Munich, Germany., Carpy A; Roche Innovation Center Munich, Germany., Bujotzek A; Roche Innovation Center Munich, Germany., Bröske AE; Roche Innovation Center Munich, Germany., Dekhtiarenko I; Roche Innovation Center Zurich, Switzerland., Attig J; Pharmaceutical Sciences, pRED, Switzerland., Kunz L; Roche Innovation Center Zurich, Switzerland., Cremasco F; Roche Innovation Center Zurich, Switzerland., Adelfio R; Roche Innovation Center Zurich, Switzerland., Fertig G; Roche Innovation Center Munich, Germany., Dengl S; Roche Innovation Center Munich, Germany., Gassner C; Roche Innovation Center Munich, Germany., Bormann F; Roche Innovation Center Munich, Germany., Kirstenpfad C; Roche Innovation Center Munich, Germany., Kraft TE; Pharmaceutical Sciences, pRED, Germany., Diggelmann S; Roche Innovation Center Zurich, Switzerland., Knobloch M; Roche Innovation Center Munich, Switzerland., Hage C; Roche Innovation Center Munich, Germany., Feddersen R; Roche Innovation Center Munich, Germany., Heidkamp G; Roche Innovation Center Munich, Germany., Pöschinger T; Roche Innovation Center Munich, Germany., Mayoux ML; University of Zurich, Zurich, Switzerland., Bernasconi L; Lonza, Basel, Switzerland., Dumontet C; Hospices Civils de Lyon, Lyon, France., Prosper F; Clinica Universidad de Navarra, Pamplona, Spain., Martinet L; CRCT, Toulouse, France., Leclair S; Roche Innovation Center Munich, Germany., Xu W; METiS Pharmaceuticals, Hangzhou, China., Paiva B; Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBERONC (CB16/12/00369), Pamplona, Spain., Klein C; Roche Innovation Center Zurich, Switzerland., Umaña P; Roche Innovation Center Zurich, Switzerland.

Publikováno v: Blood [Blood] 2024 Oct 30. Date of Electronic Publication: 2024 Oct 30.

The Tumor Milieu Promotes Functional Human Tumor-Resident Plasmacytoid Dendritic Cells in Humanized Mouse Models.

Autor: Maser IP; Roche Pharma Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, Penzberg, Germany., Hoves S; Roche Pharma Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, Penzberg, Germany., Bayer C; Roche Pharma Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, Penzberg, Germany., Heidkamp G; Roche Pharma Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, Penzberg, Germany., Nimmerjahn F; FAU Erlangen, Division of Genetics, Department of Biology, University of Erlangen-Nuremberg, Erlangen, Germany., Eckmann J; Roche Pharma Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, Penzberg, Germany., Ries CH; Roche Pharma Research and Early Development, Discovery Oncology, Roche Innovation Center Munich, Penzberg, Germany.; Dr. Carola Ries Consulting, Penzberg, Germany.

Publikováno v: Frontiers in immunology [Front Immunol] 2020 Sep 08; Vol. 11, pp. 2082. Date of Electronic Publication: 2020 Sep 08 (Print Publication: 2020).

Fetal liver CD34⁺ contain human immune and endothelial progenitors and mediate solid tumor rejection in NOG mice.

Autor: Celhar, Teja^1,2,3 (AUTHOR) teja_celhar@IDlabs.a-star.edu.sg, Li, Xinyi^1,4 (AUTHOR), Zhao, Yunqian¹ (AUTHOR), Tay, Hui Chien¹ (AUTHOR), Lee, Andrea^1,3 (AUTHOR), Liew, Hui Hua⁵ (AUTHOR), Shepherdson, Edwin Kunxiang⁵ (AUTHOR), Rajarethinam, Ravisankar⁶ (AUTHOR), Fan, Yiping^5,7,8 (AUTHOR), Mak, Anselm^9,10 (AUTHOR), Chan, Jerry Kok Yen^5,7,8 (AUTHOR), Singhal, Amit^1,3,11 (AUTHOR), Takahashi, Takeshi² (AUTHOR)

Publikováno v: Stem Cell Research & Therapy. 6/9/2024, Vol. 15 Issue 1, p1-19. 19p.

Fcγ-Receptor-Independent Controlled Activation of CD40 Canonical Signaling by Novel Therapeutic Antibodies for Cancer Therapy.

Autor: Beckmann, Karsten¹ (AUTHOR), Reitinger, Carmen² (AUTHOR), Yan, Xianglei^3,4 (AUTHOR), Carle, Anna¹ (AUTHOR), Blümle, Eva¹ (AUTHOR), Jurkschat, Nicole¹ (AUTHOR), Paulmann, Claudia¹ (AUTHOR), Prassl, Sandra¹ (AUTHOR), Kazandjian, Linda V.¹ (AUTHOR), Loré, Karin^3,4 (AUTHOR), Nimmerjahn, Falk^2,5 (AUTHOR) falk.nimmerjahn@fau.de, Fischer, Stephan⁶ (AUTHOR) falk.nimmerjahn@fau.de

Publikováno v: Antibodies (2073-4468). Jun2024, Vol. 13 Issue 2, p31. 17p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.